{"id":"W4399881301","doi":"10.1002/cncr.35387","title":"Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study","year":2024,"lang":"en","type":"article","venue":"Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba","funders":"Eisai","keywords":"Triple-negative breast cancer; Medicine; Pembrolizumab; Breast cancer; Oncology; Internal medicine; Lenvatinib; Cohort; Cancer; Triple negative; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003390964,0.0006502222,0.001113602,0.000248939,0.0003034015,0.0008570697,0.0003766391,0.0005223632,0.001738405],"category_scores_gemma":[0.001818287,0.0002716911,0.001407733,0.0003272728,0.0002465079,0.0005761929,0.0003636849,0.001157769,0.0004034625],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006270506,"about_ca_system_score_gemma":0.0009390885,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000690766,"about_ca_topic_score_gemma":0.002337274,"domain_scores_codex":[0.9990059,0.0005101587,0.00008639475,0.0001312707,0.0001819533,0.00008447515],"domain_scores_gemma":[0.9986656,0.0002825724,0.0004325155,0.0001064241,0.0001463438,0.0003666358],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6125834,0.01776368,0.1090927,0.002329703,0.01527174,0.0003514691,0.0004845454,0.002642091,0.01738772,0.0002855162,0.01669683,0.2051106],"study_design_scores_gemma":[0.4123631,0.1644817,0.3815221,0.0004605222,0.01279362,0.001278065,0.0002913563,0.003467739,0.004015828,0.0004955643,0.01871947,0.0001108957],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9828028,0.009006225,0.0004579547,0.0005892628,0.000085364,0.001202787,0.003320692,0.00004657517,0.002488331],"genre_scores_gemma":[0.9847703,0.003658422,0.0008416548,0.001007903,0.0001689049,0.001054373,0.007457712,0.00001974166,0.001020998],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003390964,"threshold_uncertainty_score":0.01793337,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01520176180571776,"score_gpt":0.3078492838161655,"score_spread":0.2926475220104477,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}